Daily Ards Research Analysis
Evidence this cycle prioritizes optimized non-invasive respiratory support in preterm infants and introduces a deep-learning approach to identify cytokine receptors relevant to cytokine storm–driven lung injury. A meta-analysis supports CPAP over HHHFNC for post-extubation support, while an RCT finds NDUOPAP comparable to NCPAP but with lower surfactant use. A computational framework (DeepCR) achieves high AUCs for cytokine receptor classification, informing future ARDS-target discovery.
Summary
Evidence this cycle prioritizes optimized non-invasive respiratory support in preterm infants and introduces a deep-learning approach to identify cytokine receptors relevant to cytokine storm–driven lung injury. A meta-analysis supports CPAP over HHHFNC for post-extubation support, while an RCT finds NDUOPAP comparable to NCPAP but with lower surfactant use. A computational framework (DeepCR) achieves high AUCs for cytokine receptor classification, informing future ARDS-target discovery.
Research Themes
- Non-invasive respiratory support strategies in preterm neonates
- Computational proteomics for cytokine receptor discovery
- Evidence synthesis guiding post-extubation care
Selected Articles
1. Comparing Heated Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure as post-extubation respiratory support in preterm infants: A comprehensive systematic review and meta-analysis.
Across nine trials (n=1471), post-extubation failure was significantly higher with HHHFNC versus CPAP overall (OR 1.61, 95% CI 1.14–2.26) and at 7 days (OR 1.65, 95% CI 1.02–2.67). CPAP was associated with more nasal trauma, while risks of BPD, ROP, NEC, PVL, IVH, and mortality did not differ.
Impact: Synthesizes randomized evidence to guide a common post-extubation decision in preterm care, balancing failure risk and device-related trauma.
Clinical Implications: Prefer CPAP over HHHFNC for post-extubation support in preterm infants to minimize failure risk, while implementing protocols to prevent nasal trauma.
Key Findings
- Overall extubation failure was higher with HHHFNC vs CPAP (OR 1.61, 95% CI 1.14–2.26).
- At 7 days, extubation failure remained higher with HHHFNC (OR 1.65, 95% CI 1.02–2.67).
- Nasal trauma occurred more often with CPAP (OR 0.20, 95% CI 0.10–0.42, favoring HHHFNC).
- No significant differences in BPD, ROP, NEC, PVL, IVH, or mortality.
Methodological Strengths
- Comprehensive multi-database search including nine clinical trials (n=1471).
- Predefined primary outcomes at 72 hours and 7 days with pooled effect estimates.
Limitations
- Potential heterogeneity across trials and variable definitions of failure and protocols.
- Risk-of-bias assessment and PRISMA adherence not detailed in the abstract.
Future Directions: Conduct head-to-head, adequately powered RCTs with standardized definitions and nasal injury prevention bundles; identify subgroups who may benefit from HHHFNC.
BackgroundThis study aims to compare the efficacy and complications of CPAP with HHHFNC, as post-extubation modalities for respiratory support in neonates.MethodsA comprehensive search was conducted in five electronic databases: MEDLINE (via PUBMED), Scopus, Web of Science, Google Scholar, and Embase in September 2022; screening observational and clinical trial studies for eligibility. Primary outcomes of the study included extubation failure at 72 hours and at 7 days.ResultsNine clinical trials were included, encompassing 1471 infants. Extubation failure at 72 days was more common with HHHFNC although insignificantly (OR = 3.40, 95% CI: 0.87, 13.23), but it was found to be significantly higher at 7 days when opting for HHHFNC (OR = 1.65, 95% CI: 1.02, 2.67). In an overall analysis, extubation failure was significantly higher in infants treated with HHHFNC (OR = 1.61, 95% CI: 1.14, 2.26). Among secondary outcomes, nasal trauma was significantly higher when CPAP was utilized (OR = 0.20 95% CI: 0.10, 0.42). Meta-analysis suggests that there are no differences in the risks for BPD (OR = 1.27, 95% CI: 0.79, 2.06), ROP (OR = 0.88, 95% CI: 0.51, 1.52), NEC (OR = 0.63, 95% CI: 0.41, 0.97), PVL (OR = 0.71, 95% CI: 0.29, 2.96), IVH (OR = 1.04, 95% CI: 0.53, 2.04), and mortality (OR = 0.96, 95% CI: 0.56, 1.66).ConclusionAccording to our review, CPAP remains the choice of non-invasive respiratory support modality regarding its lower risk for extubation failure. Although nasal trauma continues to be a challenging side effect for neonates treated with CPAP, other neonatal complications are equally prevalent when comparing CPAP and HHHFCN.
2. DeepCR: predicting cytokine receptor proteins through pretrained language models and deep learning networks.
DeepCR integrates pretrained protein language models with a multi-window CNN to classify cytokine receptor proteins directly from sequences, achieving AUCs of 0.96 (train) and 0.97/0.93 (independent tests). The approach accelerates receptor discovery relevant to cytokine storm–mediated diseases, including ARDS.
Impact: Introduces a specialized, high-performing computational framework for cytokine receptor identification, filling a methodological gap with potential downstream translational value.
Clinical Implications: While not directly clinical, DeepCR can prioritize candidate cytokine receptors for experimental validation, informing target discovery and biomarker development in ARDS and other cytokine-mediated conditions.
Key Findings
- Novel integration of pretrained protein language models (ProtTrans, ESM variants) with a multi-window CNN for receptor classification.
- High discriminative performance: AUC 0.96 (training), 0.97 and 0.93 in two independent tests.
- Eliminates manual feature engineering, enabling scalable protein classification.
Methodological Strengths
- Use of multiple pretrained language models capturing biochemical context from raw sequences.
- Independent test sets demonstrating generalization beyond training data.
Limitations
- Training dataset composition, curation, and potential class imbalance are not fully detailed in the abstract.
- Lacks experimental wet-lab validation linking predictions to receptor function in disease contexts.
Future Directions: Benchmark against broader membrane protein families, release code/data for reproducibility, and perform experimental validation in ARDS-relevant models.
Cytokine receptors play a pivotal role in mediating the immune response and are critical in cytokine storms, which underlie the pathogenesis of conditions such as acute respiratory distress syndrome (ARDS) and autoimmune disorders. Identifying cytokine receptors is essential for understanding their biological functions, exploring therapeutic targets, and guiding clinical interventions. Traditional biochemical methods to identify cytokine receptors are labor-intensive, costly, and time-consuming, prompting the need for more efficient alternatives. Recent advances in computational biology have enabled the use of machine learning to classify cytokine receptor proteins. Most existing approaches focused on homologous features and protein composition to classify cytokine families, but no dedicated studies have been conducted on cytokine receptor proteins. This gap presents an opportunity to develop a method specifically for classifying cytokine receptors among other membrane proteins. In this study, we present a novel classification framework combining pre-trained language models (PLMs) with a multi-window convolutional neural network (mCNN) architecture for the fast and accurate identification of cytokine receptor proteins. PLMs, such as ProtTrans and ESM variants, capture biochemical context directly from raw protein sequences, while mCNN efficiently extracts local and global sequence patterns using convolutional layers with varying window sizes. Our model achieved an AUC of 0.96 in the training as well as 0.97 and 0.93 in two independent tests, demonstrating its effectiveness in distinguishing cytokine receptors from non-cytokine receptor proteins. By eliminating the need for manual feature extraction, this approach offers a robust and scalable solution for protein classification, paving the way for its application in drug discovery and understanding cytokine-mediated diseases.
3. Nasal DUOPAP vs nasal continuous positive airway pressure in preterm neonates with respiratory distress syndrome - A randomized control trial.
In an open-label, non-inferiority RCT of 122 preterm neonates with RDS, NDUOPAP and NCPAP had similar failure rates within 120 hours (18% vs 19.7%; p=0.817) and comparable morbidities and support durations, but surfactant use was lower with NDUOPAP.
Impact: Provides randomized evidence comparing two widely used non-invasive modalities in preterm RDS, highlighting potential resource savings with NDUOPAP.
Clinical Implications: NDUOPAP can be considered an alternative to NCPAP for preterm RDS with similar early failure rates; the reduced surfactant need may inform protocol and resource planning.
Key Findings
- Primary outcome: no significant difference in failure within 120 hours (NDUOPAP 18% vs NCPAP 19.7%; p=0.817).
- Secondary outcomes: similar rates of PDA, pneumothorax, IVH, sepsis, NEC, apnea, BPD, ROP, and mortality.
- Surfactant requirement was lower with NDUOPAP than NCPAP (p=0.018).
Methodological Strengths
- Randomized controlled design with clearly defined primary endpoint within 120 hours.
- Balanced groups with standardized neonatal outcomes reported.
Limitations
- Open-label design may introduce performance bias.
- Single-center setting and modest sample size limit generalizability and non-inferiority precision.
Future Directions: Conduct multicenter, blinded (where feasible) non-inferiority trials with cost-effectiveness and long-term neurodevelopmental outcomes.
BACKGROUND: There has been major shift in choice of respiratory support in preterm babies from invasive to non-invasive. There are various modes of non-invasive respiratory support. The comparative efficacy of one mode over another is an important research area. OBJECTIVE: To evaluate effectiveness of Nasal duo positive airway pressure (NDUOPAP) vs nasal continuous positive airway pressure (NCPAP) in reducing need of mechanical ventilation in preterms ≤35 weeks of gestation with respiratory distress syndrome. DESIGN: Open label, non-inferiority Randomized controlled trial. SUBJECTS: 122 Neonates with GA ≤ 35 weeks (61 in NDUOPAP and 61 in NCPAP) with RDS & Silverman Andersen score ≥ 4, admitted to NICU. PRIMARY OUTCOME: Failure of allocated modes within first 120 h after birth. RESULTS: There was no significant difference between NDUOPAP: 11(18 %) and NCPAP:12(19.7 %) in treatment failure at the first 120 h of birth (p = 0.817). The morbidities including Patent Ductus Arteriosus, Pneumothorax, Intraventricular Hemorrhage, Sepsis, Necrotizing Enterocoilitis, Apnea of prematurity, Bronchopulmonary Dysplasia, Retinopathy of prematurity & mortality were similar between the two groups. The duration of non-invasive respiratory support, mechanical ventilation, oxygen therapy were also not significantly different. However the need for surfactant was lower in the NDUOPAP group when compared to NCPAP (p = 0.018). CONCLUSIONS: NDUOPAP compared to NCPAP did not reduce the need for mechanical ventilation during the first 120 h of birth in preterms with RDS.